Merck & Co., Inc. (MRK) stock
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 9/30220% above fair value
$133.72+0.91 (+0.69%)
Close on Nov 20, 2026Market cap $329.91BP/E 107.0Yield 2.45%
Merck gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
Merck's gross profit for the twelve months ending Jun 30, 2026 was $48.57B, down 0.3% year over year. For fiscal 2025 it was $48.63B, down 0.7% from the year before. Over ten years it grew 7.1% a year on average. The highest annual figure on record is $48.98B in fiscal 2024.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $48.63B | -0.7% |
| FY2024 | Dec 31, 2024 | $48.98B | +11.3% |
| FY2023 | Dec 31, 2023 | $43.99B | +5.1% |
| FY2022 | Dec 31, 2022 | $41.87B | +19.4% |
| FY2021 | Dec 31, 2021 | $35.08B | +25.7% |
| FY2020 | Dec 31, 2020 | $27.90B | +2.9% |
| FY2019 | Dec 31, 2019 | $27.11B | -5.8% |
| FY2018 | Dec 31, 2018 | $28.79B | +5.8% |
| FY2017 | Dec 31, 2017 | $27.21B | +5.6% |
| FY2016 | Dec 31, 2016 | $25.78B | +4.9% |
| FY2015 | Dec 31, 2015 | $24.56B | -3.6% |
| FY2014 | Dec 31, 2014 | $25.47B | -5.9% |
| FY2013 | Dec 31, 2013 | $27.08B | -12.1% |
| FY2012 | Dec 31, 2012 | $30.82B | -1.1% |
| FY2011 | Dec 31, 2011 | $31.18B | +13.0% |
| FY2010 | Dec 31, 2010 | $27.59B | +49.9% |
| FY2009 | Dec 31, 2009 | $18.41B | +0.8% |
| FY2008 | Dec 31, 2008 | $18.27B | +1.2% |
| FY2007 | Dec 31, 2007 | $18.06B | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $12.21B | -0.3% |
| Q1 FY2026 | Mar 31, 2026 | $12.09B | -0.2% |
| Q4 FY2025 | Dec 31, 2025 | $10.85B | -8.0% |
| Q3 FY2025 | Sep 30, 2025 | $13.42B | +6.7% |
| Q2 FY2025 | Jun 30, 2025 | $12.25B | -1.0% |
| Q1 FY2025 | Mar 31, 2025 | $12.11B | -1.0% |
| Q4 FY2024 | Dec 31, 2024 | $11.80B | +10.1% |
| Q3 FY2024 | Sep 30, 2024 | $12.58B | +7.5% |
| Q2 FY2024 | Jun 30, 2024 | $12.37B | +12.3% |
| Q1 FY2024 | Mar 31, 2024 | $12.24B | +15.9% |
| Q4 FY2023 | Dec 31, 2023 | $10.72B | +7.7% |
| Q3 FY2023 | Sep 30, 2023 | $11.70B | +6.1% |
| Q2 FY2023 | Jun 30, 2023 | $11.01B | +6.1% |
| Q1 FY2023 | Mar 31, 2023 | $10.56B | +0.4% |
| Q4 FY2022 | Dec 31, 2022 | $9.95B | +3.1% |
| Q3 FY2022 | Sep 30, 2022 | $11.03B | +13.6% |
| Q2 FY2022 | Jun 30, 2022 | $10.38B | +25.1% |
| Q1 FY2022 | Mar 31, 2022 | $10.52B | +41.6% |
| Q4 FY2021 | Dec 31, 2021 | $9.65B | +63.0% |
| Q3 FY2021 | Sep 30, 2021 | $9.70B | +22.6% |
| Q2 FY2021 | Jun 30, 2021 | $8.30B | +25.6% |
| Q1 FY2021 | Mar 31, 2021 | $7.43B | -15.1% |
| Q4 FY2020 | Dec 31, 2020 | $5.92B | +129.8% |
| Q3 FY2020 | Sep 30, 2020 | $7.92B | -5.8% |
| Q2 FY2020 | Jun 30, 2020 | $6.61B | -21.0% |
| Q1 FY2020 | Mar 31, 2020 | $8.75B | +12.6% |
| Q4 FY2019 | Dec 31, 2019 | $2.58B | -66.6% |
| Q3 FY2019 | Sep 30, 2019 | $8.41B | +17.2% |
| Q2 FY2019 | Jun 30, 2019 | $8.36B | +18.6% |
| Q1 FY2019 | Mar 31, 2019 | $7.76B | +13.3% |
| Q4 FY2018 | Dec 31, 2018 | $7.71B | +10.2% |
| Q3 FY2018 | Sep 30, 2018 | $7.18B | +2.2% |
| Q2 FY2018 | Jun 30, 2018 | $7.05B | +3.4% |
| Q1 FY2018 | Mar 31, 2018 | $6.85B | +7.3% |
| Q4 FY2017 | Dec 31, 2017 | $6.99B | +5.3% |
| Q3 FY2017 | Sep 30, 2017 | $7.02B | -1.5% |
| Q2 FY2017 | Jun 30, 2017 | $6.81B | – |
| Q1 FY2017 | Mar 31, 2017 | $6.39B | – |
| Q4 FY2016 | Dec 31, 2016 | $6.64B | – |
| Q3 FY2016 | Sep 30, 2016 | $7.13B | – |
See a number that looks wrong?